Neural Prosthetics Come Of Age As Research Continues

This summer the United States Food and Drug Administration (FDA) approved three devices intended to replace or supplement neurological function in people who are disabled. Two medical device companies are now marketing "brain pacemakers" to control epileptic seizures and to quiet the tremors of Parkinson's disease, and a third is selling a device that allows paraplegics limited control of their hands. Other neural prosthetics, most notably the cochlear implant, which can return a sense of heari

Written byRobert Finn
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

This summer the United States Food and Drug Administration (FDA) approved three devices intended to replace or supplement neurological function in people who are disabled. Two medical device companies are now marketing "brain pacemakers" to control epileptic seizures and to quiet the tremors of Parkinson's disease, and a third is selling a device that allows paraplegics limited control of their hands. Other neural prosthetics, most notably the cochlear implant, which can return a sense of hearing to some deaf people, have been in clinical use for years.

But researchers aren't resting on their laurels. Improvements are under way in all of these devices, and many others are in various stages of development. While most of the current devices perform relatively simple stimulation of peripheral nerves or deep brain structures, some researchers believe the world is not far from a science-fiction future in which silicon chips performing advanced computations will be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies